Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myogen has revealed positive top line results from its second pivotal phase III trial evaluating its investigational drug ambrisentan in pulmonary arterial hypertension.
Subscribe to our email newsletter
The trial met the primary efficacy endpoint of improved exercise capacity for both ambrisentan dose groups, with a good safety profile and no observed liver function abnormalities in the ambrisentan treatment groups.
On the basis of the results of the two pivotal trials, Myogen expects to submit a new drug application to the FDA for ambrisentan in the fourth quarter of 2006.
Results of the trial demonstrated that with once-daily dosing, 10 mg of ambrisentan improved the placebo-corrected mean six-minute walk distance (6MWD) by 51.4 meters and 5 mg of ambrisentan improved the placebo-corrected mean 6MWD by 30.6 meters, indicating improved exercise capacity.
These results trigger a $5.25 million milestone payment under Myogen’s ambrisentan sublicense agreement with GlaxoSmithKline.
“With two positive, well-controlled studies demonstrating robust efficacy and a safety database of more than 400 patients on long-term treatment, we have the foundation for high quality regulatory submissions worldwide,” said Dr Michael Gerber, senior vice president of clinical development and regulatory affairs for Myogen.